We are Changing the Drug Discovery Paradigm

Congruence Therapeutics is a drug discovery company harnessing the power of innovative fields such as protein dynamics, biophysics, machine learning and computational chemistry.

We have a uniquely qualified team, founded by serial life sciences entrepreneur Clarissa Desjardins, PhD, most recently the founder and CEO of rare disease company Clementia Pharmaceuticals (Nasdaq: CMTA) sold to Ipsen for US$1.31 billion in 2019.  Learn more about our outstanding team below.


Chief Executive Officer
Chief Operating Officer
Chief Scientific Officer
EVP Corporate and Business Development
Director of Computational Molecular Sciences
Vice President Chemistry
Chief Innovation Officer
Vice President Discovery Research
Vice President of Finance

Board of Directors & Observers


In December 2021, we completed a Series A financing of US$50 million with top U.S. and Canadian investors, including OrbiMed, Amplitude Ventures, and Driehaus.